Dechra Pharmaceuticals (OTCMKTS:DCHPF) Price Target Lowered to GBX 4,000 at JPMorgan Chase & Co.

Dechra Pharmaceuticals (OTCMKTS:DCHPF – Get Rating) had its price objective lowered by JPMorgan Chase & Co. from GBX 4,600 ($55.32) to GBX 4,000 ($48.10) in a report released on Tuesday morning, The Fly reports.

DCHPF has been the topic of a number of other research reports. Panmure Gordon raised Dechra Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, January 12th. Liberum Capital raised Dechra Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, January 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Dechra Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus price target of $4,000.00.

Dechra Pharmaceuticals Price Performance

DCHPF opened at $37.10 on Tuesday. Dechra Pharmaceuticals has a 52 week low of $27.90 and a 52 week high of $54.93. The business’s fifty day simple moving average is $34.47 and its 200 day simple moving average is $35.02.

About Dechra Pharmaceuticals

(Get Rating)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.